50+ years of representing the T1D community

Breakthrough T1D was founded by Lee Ducat, Carol Lurie, Erwin Lurie, and a group of parents whose children have T1D. They were dedicated to finding a cure.

This was the beginning of a revolutionary way to manage insulin therapy.

This was a huge step forward, leading to a lower risk of immune reactions and better blood sugar control than animal insulin.

Bringing the scientific breakthrough to the T1D community in Australia.

By parents with a shared goal for cures for their children who were diagnosed with T1D.

At the time, Dr Silink was the only endocrinologist in Sydney. 

Performed by a Breakthrough T1D-funded researcher in the U.S.

An amazing outcome resulting from Breakthrough T1D's advocacy.

Giving access to insulin pumps for families who could not otherwise afford them.

This lead to acceleration of continuous glucose monitoring technology, now widely available and accessible in Australia.

This is the Type 1 Diabetes Clinical Research Network, which has grown to be one of the leading funders of T1D research in Australia. The Government also committed additional funding in 2013 and 2019.

This is the Environmental Determinants of Islet Autoimmunity Study, the world’s largest study into environmental factors that cause T1D, starting from pregnancy.

This represents another way to live insulin-free, with significant research funding now invested in this area.

This included access for children and young adults up to the age of 21, as well as new and expectant mothers.

Utilising the immunotherapy drug, teplizumab. Breakthrough T1D-funded Australian researchers played an integral role in this discovery.

Investigating whether the drug, baricitinib has the potential to slow or stop the onset of T1D.

The Australasian Type 1 Diabetes Immunotherapy Collaborative commenced with Breakthrough T1D funding, aiming to bring T1D clinical trials to Australia.

Aiming to determine the best way to introduce childhood T1D screening, to ensure early detection for every child in Australia and avoid critical illness at the point of diagnosis.

Thanks to Breakthrough T1D's advocacy securing a $273.1Mm bipartisan commitment for the subsidisation. The technology is now accessible for every Australian with T1D, regardless of their age or income.

Lead by Breakthrough T1D-funded Australian researchers, the project is testing a novel approach of transplantation under the skin.

The first new therapy for T1D approved since insulin.

Supporting the T1DCRN for a further five years, looking into T1D prevention, precision medicine, and progress towards cures.